Abciximab readministration: Results of the ReoPro Readministration Registry Academic Article uri icon

Overview

MeSH Major

  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal
  • Coronary Disease
  • Immunoglobulin Fab Fragments
  • Registries
  • Thrombocytopenia
  • Vascular Patency

abstract

  • The results, including overall rates of thrombocytopenia, were consistent with randomized clinical trials of first abciximab treatment. However, there was a shift from mild to profound thrombocytopenia, and cases of delayed presentation and of recurrent thrombocytopenia were seen. These findings suggest that indications and guidelines for first-time use apply to retreatment, particularly the systematic monitoring for thrombocytopenia.

publication date

  • August 21, 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11514371

Additional Document Info

start page

  • 870

end page

  • 5

volume

  • 104

number

  • 8